or Try an Advanced Search...

    Technical Analysis for ACLX - Arcellx, Inc.

    Grade Last Price % Change Price Change
    D 53.66 2.84% 1.48
    ACLX closed up 4.32 percent on Wednesday, May 1, 2024, on 1.15 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 8
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Up
    Historical ACLX trend table...
    Date Alert Name Type % Chg
    Oversold Stochastic Weakness 2.84%
    NR7 Range Contraction 7.28%
    Multiple of Ten Bullish Other 7.28%
    Wide Bands Range Expansion 7.28%
    Oversold Stochastic Weakness 7.28%
    Wide Bands Range Expansion 4.99%
    Oversold Stochastic Weakness 4.99%
    Slingshot Bearish Bearish Swing Setup 3.35%
    Bullish Engulfing Bullish 3.35%
    NR7 Range Contraction 3.35%
    Older End-of-Day Signals for ACLX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 3 hours ago
    Up 3% about 3 hours ago
    Up 2% about 5 hours ago
    60 Minute Opening Range Breakout about 5 hours ago
    Up 1% about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ACLX Chart by TradingView
    Basic chart:

    Profile

    Arcellx, Inc. Description

    Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Organ Systems Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Protein Kinase Inhibitor Myelodysplastic Syndrome Antibody Drug Conjugate

    Is ACLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 23 Should You Be Bullish on Arcellx (ACLX)?
    Apr 15 Peering Into Arcellx's Recent Short Interest
    Apr 4 Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Apr 4 How Arcellx (ACLX) Stock Stands Out in a Strong Industry
    Mar 29 Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors
    Mar 28 Insiders Are Dumping These 10 Healthcare Stocks
    Mar 27 Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
    Mar 20 Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
    Mar 2 Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates
    Feb 29 Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
    See more ACLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 75.1
    52 Week Low 30.78
    Average Volume 470,846
    200-Day Moving Average 49.28
    50-Day Moving Average 63.16
    20-Day Moving Average 55.53
    10-Day Moving Average 52.20
    Average True Range 2.69
    RSI (14) 36.71
    ADX 39.89
    +DI 16.71
    -DI 29.21
    Chandelier Exit (Long, 3 ATRs) 58.11
    Chandelier Exit (Short, 3 ATRs) 57.72
    Upper Bollinger Bands 63.45
    Lower Bollinger Band 47.60
    Percent B (%b) 0.29
    BandWidth 28.54
    MACD Line -3.68
    MACD Signal Line -3.56
    MACD Histogram -0.1138
    Fundamentals Value
    Market Cap 2.71 Billion
    Num Shares 51.9 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -19.69
    Price-to-Sales 71.43
    Price-to-Book 12.01
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 57.85
    Resistance 3 (R3) 57.82 55.89 56.91
    Resistance 2 (R2) 55.89 54.45 55.91 56.59
    Resistance 1 (R1) 54.04 53.56 54.97 54.07 56.27
    Pivot Point 52.11 52.11 52.58 52.13 52.11
    Support 1 (S1) 50.26 50.67 51.19 50.29 48.09
    Support 2 (S2) 48.33 49.78 48.35 47.77
    Support 3 (S3) 46.48 48.33 47.46
    Support 4 (S4) 46.51